» Articles » PMID: 25183580

Classification of Hypervascular Liver Lesions Based on Hepatic Artery and Portal Vein Blood Supply Coefficients Calculated from Triphasic CT Scans

Overview
Journal J Digit Imaging
Publisher Springer
Date 2014 Sep 4
PMID 25183580
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Perfusion CT of the liver typically involves scanning the liver at least 20 times, resulting in a large radiation dose. We developed and validated a simplified model of tumor blood supply that can be applied to standard triphasic scans and evaluated whether this can be used to distinguish benign and malignant liver lesions. Triphasic CTs of 46 malignant and 32 benign liver lesions were analyzed. For each phase, regions of interest were drawn in the arterially enhancing portion of each lesion, as well as the background liver, aorta, and portal vein. Hepatic artery and portal vein blood supply coefficients for each lesion were then calculated by expressing the enhancement curve of the lesion as a linear combination of the enhancement curves of the aorta and portal vein. Hepatocellular carcinoma (HCC) and hypervascular metastases, on average, both had increased hepatic artery coefficients compared to the background liver. Compared to HCC, benign lesions, on average, had either a greater hepatic artery coefficient (hemangioma) or a greater portal vein coefficient (focal nodular hyperplasia or transient hepatic attenuation difference). Hypervascularity with washout is a key diagnostic criterion for HCC, but it had a sensitivity of 72 % and specificity of 81 % for diagnosing malignancy in our diverse set of liver lesions. The sensitivity for malignancy was increased to 89 % by including enhancing lesions that were hypodense on all phases. The specificity for malignancy was increased to 97 % (p = 0.039) by also examining hepatic artery and portal vein blood supply coefficients, while maintaining a sensitivity of 76 %.

Citing Articles

Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study.

Li Y, Wu S, Wu Y, Zhang W, Wang Y, Li Y J Hepatocell Carcinoma. 2024; 11:1389-1402.

PMID: 39011125 PMC: 11247128. DOI: 10.2147/JHC.S462168.


Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.

Zheng S, Chan S, Liu F, Liu J, Chow P, Toh H Cancers (Basel). 2024; 16(8).

PMID: 38672664 PMC: 11048862. DOI: 10.3390/cancers16081582.


The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).

Quartuccio N, Ialuna S, Scalisi D, DAmato F, Barcellona M, Bavetta M Curr Oncol. 2024; 31(3):1504-1514.

PMID: 38534947 PMC: 10969045. DOI: 10.3390/curroncol31030114.


Underestimation of liver hemangioma perfusion fraction by standard intravoxel incoherent motion diffusion magnetic resonance imaging.

Wang Y, Sabarudin A Quant Imaging Med Surg. 2024; 14(2):2128-2135.

PMID: 38415141 PMC: 10895138. DOI: 10.21037/qims-23-1651.


Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.

Zhang L, Pang G, Zhang J, Yuan Z Sci Rep. 2023; 13(1):8629.

PMID: 37244941 PMC: 10224972. DOI: 10.1038/s41598-023-35913-y.


References
1.
Ichikawa T, Federle M, Grazioli L, Nalesnik M . Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology. 2000; 214(3):861-8. DOI: 10.1148/radiology.214.3.r00mr28861. View

2.
Kim S, Kim S, Lee J, Kim M, Jeon Y, Park Y . Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009; 192(6):1675-81. DOI: 10.2214/AJR.08.1262. View

3.
Li J, Zhao D, Jiang H, Huang Y, Li D, Wan Y . Assessment of tumor vascularization with functional computed tomography perfusion imaging in patients with cirrhotic liver disease. Hepatobiliary Pancreat Dis Int. 2011; 10(1):43-9. DOI: 10.1016/s1499-3872(11)60006-4. View

4.
. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

5.
Doyle D, OMalley M, Jang H, Jhaveri K . Value of the unenhanced phase for detection of hepatocellular carcinomas 3 cm or less when performing multiphase computed tomography in patients with cirrhosis. J Comput Assist Tomogr. 2007; 31(1):86-92. DOI: 10.1097/01.rct.0000233126.21303.f0. View